Pattern of metastatic spread in triple-negative breast cancer - PubMed (original) (raw)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al. Breast Cancer Res Treat. 2009 May.
Abstract
Purpose: The prognosis of women with triple-negative breast cancers (defined as cancers that are estrogen receptor-negative, progesterone receptor-negative and HER2/neu negative) is poor, compared to women with other subtypes of breast cancer. It is proposed that the underlying difference in recurrence rates may be explained in part by different routes of metastatic spread.
Experimental design: We studied a cohort of 1608 patients diagnosed with breast cancer, diagnosed between January 1987 and December 1997 at Women's College Hospital in Toronto. Triple-negative breast cancers were defined as those that were estrogen receptor-negative, progesterone receptor-negative and HER2/neu-negative. We compared the incidence rates of metastatic spread to bone and to other (non-bone) organs in women with triple-negative and other forms of breast cancer.
Results: Of the 1,608 patients, 180 (11.2%) had triple-negative breast cancer. The 1608 women were followed for a median of 9.0 years (range 0.1-19 years). Compared to other patients, those with triple-negative breast cancer had an increased likelihood of distant recurrence over the study period (adjusted hazard ratio (HR) 1.9; 95% CI: 1.5-2.5, P < 0.0001). The relatively poor prognosis was apparent in the five years after diagnosis (HR 2.9; 95% CI: 2.1-3.9; P = 0.0001) but not thereafter (HR 0.5; 95% CI: 0.2-1.1; P = 0.07). In particular, women with triple-negative breast cancer were four times more likely to experience a visceral metastasis within five years of diagnosis than those with other types of cancer (HR 4.0; 95% CI: 2.7-5.9; P < 0.0001). The rates of bone metastases were comparable for triple-negative and for other forms of cancer in this time period (HR 0.8; 95% CI: 0.4-1.6 P = 0.5).
Conclusions: The excess risk of distant recurrence in triple-negative breast cancers, versus other forms of cancer, is attributable in large part to an excess of visceral metastases in the first five years following diagnosis.
Similar articles
- Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Haffty BG, et al. J Clin Oncol. 2006 Dec 20;24(36):5652-7. doi: 10.1200/JCO.2006.06.5664. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116942 - Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A. Heitz F, et al. Eur J Cancer. 2009 Nov;45(16):2792-8. doi: 10.1016/j.ejca.2009.06.027. Epub 2009 Jul 28. Eur J Cancer. 2009. PMID: 19643597 - T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG, Malmgren JA, Atwood M. Kaplan HG, et al. Breast J. 2009 Sep-Oct;15(5):454-60. doi: 10.1111/j.1524-4741.2009.00789.x. Epub 2009 Aug 4. Breast J. 2009. PMID: 19671105 - What is triple-negative breast cancer?
Irvin WJ Jr, Carey LA. Irvin WJ Jr, et al. Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Eur J Cancer. 2008. PMID: 19008097 Review. - Triple-negative breast cancer: a short review.
Elias AD. Elias AD. Am J Clin Oncol. 2010 Dec;33(6):637-45. doi: 10.1097/COC.0b013e3181b8afcf. Am J Clin Oncol. 2010. PMID: 20023571 Review.
Cited by
- Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.
Volk-Draper LD, Rajput S, Hall KL, Wilber A, Ran S. Volk-Draper LD, et al. Neoplasia. 2012 Oct;14(10):926-42. doi: 10.1593/neo.12956. Neoplasia. 2012. PMID: 23097627 Free PMC article. - Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH. Gupta GK, et al. Cancers (Basel). 2020 Aug 24;12(9):2392. doi: 10.3390/cancers12092392. Cancers (Basel). 2020. PMID: 32846967 Free PMC article. Review. - An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer.
Li H, Duhachek-Muggy S, Qi Y, Hong Y, Behbod F, Zolkiewska A. Li H, et al. Breast Cancer Res Treat. 2012 Oct;135(3):759-69. doi: 10.1007/s10549-012-2220-4. Epub 2012 Aug 29. Breast Cancer Res Treat. 2012. PMID: 22926263 Free PMC article. - MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.
Oudin MJ, Barbier L, Schäfer C, Kosciuk T, Miller MA, Han S, Jonas O, Lauffenburger DA, Gertler FB. Oudin MJ, et al. Mol Cancer Ther. 2017 Jan;16(1):143-155. doi: 10.1158/1535-7163.MCT-16-0413. Epub 2016 Nov 3. Mol Cancer Ther. 2017. PMID: 27811011 Free PMC article. - Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice.
Roberti MP, Arriaga JM, Bianchini M, Quintá HR, Bravo AI, Levy EM, Mordoh J, Barrio MM. Roberti MP, et al. Cancer Biol Ther. 2012 Sep;13(11):1123-40. doi: 10.4161/cbt.21187. Epub 2012 Jul 24. Cancer Biol Ther. 2012. PMID: 22825326 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous